And it will be in effect tomorrow as I understand it.
All eyes have to be on Sanofi with this lawsuit by Genzyme regarding their MS drug. Sanofi is going to have to put on a decent show with respect to Mannkind in light of this - IMO. That said, I wish Viehbacher hadn't been ousted.
Furthermore, the alternative uptick rule and circuit breaker will be in effect tomorrow since today's decline was more than 10% Hopefully this will prevent the pps from getting crushed. It seems to me that someone was working really hard to keep this at a greater than 10% decline in order to suppress a decline tomorrow. Shorts didn't appear to be in control based on what I was seeing on level 2. Tomorrow should be interesting. JMHO
At least that is how I understand the current uptick rule. $2.367 is a 10% decline from yesterday's close. As I understand it, if a stock closes more than 10% down by the end of the day, then shorting is not permitted the next day. Please correct me if I'm wrong. If I am correct, being unable to short tomorrow could put shorts in a precarious position vis a vis the Israeli deal. Comments appreciated.
I'm afraid I don't see shorts covering at this point. I don't think they'll stop til they see Mannkind destroyed. The only saving grace is that if the stock closes down 10% today, shorts will not be able to short tomorrow, and then hopefully the Israeli transaction will be complete before US pre-market to help stabilize the price in the near term.
The value of just about all of mnkd calls has been crushed while most of the puts are deep in the money. I've noticed in the past that it's the calls, regardless of the puts' status, that tend to get crushed, but things are so lopsided I'm not sure if things will play out that way this week. I'm not an options expert, which is why I don't play them, so I'd appreciate any insight.
No they didn't finish it - they just started the recruiting for the study as you say. You must've missed that I said "commencement".
Inclusion of Afrezza in Praluent study
Commencement of pediatric trials
Completion of Afrezza clamp studies
Direct mail pamphlets to diabetics
Video publicity drive targeting local news stations.
New video for "meet Afrezza" that is clearly professionally done
This are not the signs of a company throwing in the towel on Afrezza.
Well I checked his profile out but I still don't know what you're talking about. Why not just post what you've discovered? Playing this game is silly.
We've seen a video publicity effort aimed at local news stations and direct mail pamphlet sent directly to consumers - the latter does not come cheap. Granted we are far away from a full out marketing blitz but still, why would SNY add fuel to fire by continuing to spend dollars that add to mnkd's costs? I am concerned as anyone about today's action but what we know about mnkd's finances vs. what SNY is doing doesn't add up to me.
Lung delivery of human insulin is what makes this product unique. Inject it and you might as well go with Lantus or another basal insulin.
I would add - Please tell us the SEC has been investigating pps manipulation by shorts and that the perpetrators will soon be identified and charged.
Thank you. Makes no sense to me that they would reaffirm on a Sunday morning and just before mnkd's earnings release and cc. But then again, when does anything ever make sense with respect to mnkd.